Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities
A new series of naphthyl chalcones ( 3a – 3p ) and their pyrazoline derivatives ( 4a – 4h ) were synthesized using substituted acetophenones, substituted naphthaldehydes, and hydrazine hydrate as starting materials. All the synthesized compounds were characterized by IR, NMR, and mass spectrometric...
Gespeichert in:
Veröffentlicht in: | Medicinal chemistry research 2020-10, Vol.29 (10), p.1819-1835 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1835 |
---|---|
container_issue | 10 |
container_start_page | 1819 |
container_title | Medicinal chemistry research |
container_volume | 29 |
creator | Pola, Shivani Banoth, Karan Kumar Sankaranarayanan, Murugesan Ummani, Ramesh Garlapati, Achaiah |
description | A new series of naphthyl chalcones (
3a
–
3p
) and their pyrazoline derivatives (
4a
–
4h
) were synthesized using substituted acetophenones, substituted naphthaldehydes, and hydrazine hydrate as starting materials. All the synthesized compounds were characterized by IR, NMR, and mass spectrometric analysis and screened for antimycobacterial activity against
Mycobacterium tuberculosis H37Rv (ATCC 27924)
and antibacterial activity against
Staphylococcus aureus (MTCC 96), Bacillus subtilis (MTCC 441), Escherichia coli (MTCC 443) and Klebsiella pneumonia (MTCC 109)
. Compounds
3b
and
3p
exhibited significant antibacterial activity against all the tested bacterial strains. Amongst the synthesized compounds, compound
4b
with 2-hydroxy-5-bromophenyl substitution at 3rd position of pyrazoline showed significant antimycobacterial activity with MIC of 6.25 µM comparable to that of standard isoniazid. The synthesized compounds were further screened for their cytotoxic activity against the MDA-MB-231 and SKOV3 cell lines. The compounds
3a
,
3l
,
4b
,
4c
,
4e
, and
4h
did not exhibit any cytotoxicity, and other compounds exhibited IC
50
values higher than 8 and 22 µM against MDA-MB-231 and SKOV3 cell lines, respectively, compared to 1.20 and 1.30 µM shown by standard doxorubicin. To find out the putative binding mode of significantly active and weakly active compounds, a molecular docking study was also performed. In that, the most active compound
4b
, displayed a hydrogen bond interaction with docking score of −10.50 kcal/mol and energy of −44.50 weakly active compound
3h
did not show any crucial hydrogen bond interaction with the surrounded amino-acid residues and revealed a docking score of −6.74 and docking energy of −42.50. |
doi_str_mv | 10.1007/s00044-020-02602-8 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2438213617</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2438213617</sourcerecordid><originalsourceid>FETCH-LOGICAL-c319t-93af2fdbcdf890503b9d29d05dce4ae82d9f5896eb5fb4457059331612f3ebed3</originalsourceid><addsrcrecordid>eNp9kc1KJDEUhQsZQUd9AVcBt5Zzk1S6q5bi-DMguJlZh1Ryo5EyaZNUQ_skPq7X7gF3LkIOh--cuzhNc8rhggMsfxUA6LoWBNBbgGj7veaQK9W1PRfwgzSQFkrIg-ZnKc8AcgmdOmzef2MJj_GclU2sT6TLOQuRlTAFm1ipswtIlomO4dpMs6khRZY8i2mNE7NPZrIpYtkSVBAyW22yeUtTiMgc5rCmyJoAnzJBNYzGVrLNtI18OnUeMdt5MgRYgkOlm8fNvjdTwZP__1Hz7-b679Vde_9w--fq8r61kg-1HaTxwrvROt8PoECOgxODA-UsdgZ74Qav-mGBo_Jj16klqEFKvuDCSxzRyaPmbNe7yul1xlL1c5pzpJNadLIXXC74kiixo2xOpWT0epXDi8kbzUF_LqB3C2haQG8X0D2F5C5UCI6PmL-qv0l9AEPqjTM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2438213617</pqid></control><display><type>article</type><title>Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities</title><source>SpringerLink Journals - AutoHoldings</source><creator>Pola, Shivani ; Banoth, Karan Kumar ; Sankaranarayanan, Murugesan ; Ummani, Ramesh ; Garlapati, Achaiah</creator><creatorcontrib>Pola, Shivani ; Banoth, Karan Kumar ; Sankaranarayanan, Murugesan ; Ummani, Ramesh ; Garlapati, Achaiah</creatorcontrib><description>A new series of naphthyl chalcones (
3a
–
3p
) and their pyrazoline derivatives (
4a
–
4h
) were synthesized using substituted acetophenones, substituted naphthaldehydes, and hydrazine hydrate as starting materials. All the synthesized compounds were characterized by IR, NMR, and mass spectrometric analysis and screened for antimycobacterial activity against
Mycobacterium tuberculosis H37Rv (ATCC 27924)
and antibacterial activity against
Staphylococcus aureus (MTCC 96), Bacillus subtilis (MTCC 441), Escherichia coli (MTCC 443) and Klebsiella pneumonia (MTCC 109)
. Compounds
3b
and
3p
exhibited significant antibacterial activity against all the tested bacterial strains. Amongst the synthesized compounds, compound
4b
with 2-hydroxy-5-bromophenyl substitution at 3rd position of pyrazoline showed significant antimycobacterial activity with MIC of 6.25 µM comparable to that of standard isoniazid. The synthesized compounds were further screened for their cytotoxic activity against the MDA-MB-231 and SKOV3 cell lines. The compounds
3a
,
3l
,
4b
,
4c
,
4e
, and
4h
did not exhibit any cytotoxicity, and other compounds exhibited IC
50
values higher than 8 and 22 µM against MDA-MB-231 and SKOV3 cell lines, respectively, compared to 1.20 and 1.30 µM shown by standard doxorubicin. To find out the putative binding mode of significantly active and weakly active compounds, a molecular docking study was also performed. In that, the most active compound
4b
, displayed a hydrogen bond interaction with docking score of −10.50 kcal/mol and energy of −44.50 weakly active compound
3h
did not show any crucial hydrogen bond interaction with the surrounded amino-acid residues and revealed a docking score of −6.74 and docking energy of −42.50.</description><identifier>ISSN: 1054-2523</identifier><identifier>EISSN: 1554-8120</identifier><identifier>DOI: 10.1007/s00044-020-02602-8</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Amino acids ; Antibacterial activity ; Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Bioorganic Chemistry ; Biotechnology ; Cell lines ; Cytotoxicity ; Derivatives ; Doxorubicin ; E coli ; Hydrazine ; Hydrazines ; Hydrogen bonds ; Inorganic Chemistry ; Isoniazid ; Klebsiella ; Medicinal Chemistry ; Minimum inhibitory concentration ; Molecular docking ; NMR ; Nuclear magnetic resonance ; Original Research ; Pharmacology/Toxicology ; Spectrometry ; Substitutes ; Synthesis ; Toxicity ; Tuberculosis</subject><ispartof>Medicinal chemistry research, 2020-10, Vol.29 (10), p.1819-1835</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c319t-93af2fdbcdf890503b9d29d05dce4ae82d9f5896eb5fb4457059331612f3ebed3</citedby><cites>FETCH-LOGICAL-c319t-93af2fdbcdf890503b9d29d05dce4ae82d9f5896eb5fb4457059331612f3ebed3</cites><orcidid>0000-0002-6699-4744</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00044-020-02602-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00044-020-02602-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Pola, Shivani</creatorcontrib><creatorcontrib>Banoth, Karan Kumar</creatorcontrib><creatorcontrib>Sankaranarayanan, Murugesan</creatorcontrib><creatorcontrib>Ummani, Ramesh</creatorcontrib><creatorcontrib>Garlapati, Achaiah</creatorcontrib><title>Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities</title><title>Medicinal chemistry research</title><addtitle>Med Chem Res</addtitle><description>A new series of naphthyl chalcones (
3a
–
3p
) and their pyrazoline derivatives (
4a
–
4h
) were synthesized using substituted acetophenones, substituted naphthaldehydes, and hydrazine hydrate as starting materials. All the synthesized compounds were characterized by IR, NMR, and mass spectrometric analysis and screened for antimycobacterial activity against
Mycobacterium tuberculosis H37Rv (ATCC 27924)
and antibacterial activity against
Staphylococcus aureus (MTCC 96), Bacillus subtilis (MTCC 441), Escherichia coli (MTCC 443) and Klebsiella pneumonia (MTCC 109)
. Compounds
3b
and
3p
exhibited significant antibacterial activity against all the tested bacterial strains. Amongst the synthesized compounds, compound
4b
with 2-hydroxy-5-bromophenyl substitution at 3rd position of pyrazoline showed significant antimycobacterial activity with MIC of 6.25 µM comparable to that of standard isoniazid. The synthesized compounds were further screened for their cytotoxic activity against the MDA-MB-231 and SKOV3 cell lines. The compounds
3a
,
3l
,
4b
,
4c
,
4e
, and
4h
did not exhibit any cytotoxicity, and other compounds exhibited IC
50
values higher than 8 and 22 µM against MDA-MB-231 and SKOV3 cell lines, respectively, compared to 1.20 and 1.30 µM shown by standard doxorubicin. To find out the putative binding mode of significantly active and weakly active compounds, a molecular docking study was also performed. In that, the most active compound
4b
, displayed a hydrogen bond interaction with docking score of −10.50 kcal/mol and energy of −44.50 weakly active compound
3h
did not show any crucial hydrogen bond interaction with the surrounded amino-acid residues and revealed a docking score of −6.74 and docking energy of −42.50.</description><subject>Amino acids</subject><subject>Antibacterial activity</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bioorganic Chemistry</subject><subject>Biotechnology</subject><subject>Cell lines</subject><subject>Cytotoxicity</subject><subject>Derivatives</subject><subject>Doxorubicin</subject><subject>E coli</subject><subject>Hydrazine</subject><subject>Hydrazines</subject><subject>Hydrogen bonds</subject><subject>Inorganic Chemistry</subject><subject>Isoniazid</subject><subject>Klebsiella</subject><subject>Medicinal Chemistry</subject><subject>Minimum inhibitory concentration</subject><subject>Molecular docking</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Original Research</subject><subject>Pharmacology/Toxicology</subject><subject>Spectrometry</subject><subject>Substitutes</subject><subject>Synthesis</subject><subject>Toxicity</subject><subject>Tuberculosis</subject><issn>1054-2523</issn><issn>1554-8120</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kc1KJDEUhQsZQUd9AVcBt5Zzk1S6q5bi-DMguJlZh1Ryo5EyaZNUQ_skPq7X7gF3LkIOh--cuzhNc8rhggMsfxUA6LoWBNBbgGj7veaQK9W1PRfwgzSQFkrIg-ZnKc8AcgmdOmzef2MJj_GclU2sT6TLOQuRlTAFm1ipswtIlomO4dpMs6khRZY8i2mNE7NPZrIpYtkSVBAyW22yeUtTiMgc5rCmyJoAnzJBNYzGVrLNtI18OnUeMdt5MgRYgkOlm8fNvjdTwZP__1Hz7-b679Vde_9w--fq8r61kg-1HaTxwrvROt8PoECOgxODA-UsdgZ74Qav-mGBo_Jj16klqEFKvuDCSxzRyaPmbNe7yul1xlL1c5pzpJNadLIXXC74kiixo2xOpWT0epXDi8kbzUF_LqB3C2haQG8X0D2F5C5UCI6PmL-qv0l9AEPqjTM</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Pola, Shivani</creator><creator>Banoth, Karan Kumar</creator><creator>Sankaranarayanan, Murugesan</creator><creator>Ummani, Ramesh</creator><creator>Garlapati, Achaiah</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>M7Z</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0002-6699-4744</orcidid></search><sort><creationdate>20201001</creationdate><title>Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities</title><author>Pola, Shivani ; Banoth, Karan Kumar ; Sankaranarayanan, Murugesan ; Ummani, Ramesh ; Garlapati, Achaiah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c319t-93af2fdbcdf890503b9d29d05dce4ae82d9f5896eb5fb4457059331612f3ebed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Amino acids</topic><topic>Antibacterial activity</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bioorganic Chemistry</topic><topic>Biotechnology</topic><topic>Cell lines</topic><topic>Cytotoxicity</topic><topic>Derivatives</topic><topic>Doxorubicin</topic><topic>E coli</topic><topic>Hydrazine</topic><topic>Hydrazines</topic><topic>Hydrogen bonds</topic><topic>Inorganic Chemistry</topic><topic>Isoniazid</topic><topic>Klebsiella</topic><topic>Medicinal Chemistry</topic><topic>Minimum inhibitory concentration</topic><topic>Molecular docking</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Original Research</topic><topic>Pharmacology/Toxicology</topic><topic>Spectrometry</topic><topic>Substitutes</topic><topic>Synthesis</topic><topic>Toxicity</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pola, Shivani</creatorcontrib><creatorcontrib>Banoth, Karan Kumar</creatorcontrib><creatorcontrib>Sankaranarayanan, Murugesan</creatorcontrib><creatorcontrib>Ummani, Ramesh</creatorcontrib><creatorcontrib>Garlapati, Achaiah</creatorcontrib><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Medicinal chemistry research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pola, Shivani</au><au>Banoth, Karan Kumar</au><au>Sankaranarayanan, Murugesan</au><au>Ummani, Ramesh</au><au>Garlapati, Achaiah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities</atitle><jtitle>Medicinal chemistry research</jtitle><stitle>Med Chem Res</stitle><date>2020-10-01</date><risdate>2020</risdate><volume>29</volume><issue>10</issue><spage>1819</spage><epage>1835</epage><pages>1819-1835</pages><issn>1054-2523</issn><eissn>1554-8120</eissn><abstract>A new series of naphthyl chalcones (
3a
–
3p
) and their pyrazoline derivatives (
4a
–
4h
) were synthesized using substituted acetophenones, substituted naphthaldehydes, and hydrazine hydrate as starting materials. All the synthesized compounds were characterized by IR, NMR, and mass spectrometric analysis and screened for antimycobacterial activity against
Mycobacterium tuberculosis H37Rv (ATCC 27924)
and antibacterial activity against
Staphylococcus aureus (MTCC 96), Bacillus subtilis (MTCC 441), Escherichia coli (MTCC 443) and Klebsiella pneumonia (MTCC 109)
. Compounds
3b
and
3p
exhibited significant antibacterial activity against all the tested bacterial strains. Amongst the synthesized compounds, compound
4b
with 2-hydroxy-5-bromophenyl substitution at 3rd position of pyrazoline showed significant antimycobacterial activity with MIC of 6.25 µM comparable to that of standard isoniazid. The synthesized compounds were further screened for their cytotoxic activity against the MDA-MB-231 and SKOV3 cell lines. The compounds
3a
,
3l
,
4b
,
4c
,
4e
, and
4h
did not exhibit any cytotoxicity, and other compounds exhibited IC
50
values higher than 8 and 22 µM against MDA-MB-231 and SKOV3 cell lines, respectively, compared to 1.20 and 1.30 µM shown by standard doxorubicin. To find out the putative binding mode of significantly active and weakly active compounds, a molecular docking study was also performed. In that, the most active compound
4b
, displayed a hydrogen bond interaction with docking score of −10.50 kcal/mol and energy of −44.50 weakly active compound
3h
did not show any crucial hydrogen bond interaction with the surrounded amino-acid residues and revealed a docking score of −6.74 and docking energy of −42.50.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s00044-020-02602-8</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0002-6699-4744</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1054-2523 |
ispartof | Medicinal chemistry research, 2020-10, Vol.29 (10), p.1819-1835 |
issn | 1054-2523 1554-8120 |
language | eng |
recordid | cdi_proquest_journals_2438213617 |
source | SpringerLink Journals - AutoHoldings |
subjects | Amino acids Antibacterial activity Biochemistry Biomedical and Life Sciences Biomedicine Bioorganic Chemistry Biotechnology Cell lines Cytotoxicity Derivatives Doxorubicin E coli Hydrazine Hydrazines Hydrogen bonds Inorganic Chemistry Isoniazid Klebsiella Medicinal Chemistry Minimum inhibitory concentration Molecular docking NMR Nuclear magnetic resonance Original Research Pharmacology/Toxicology Spectrometry Substitutes Synthesis Toxicity Tuberculosis |
title | Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T22%3A58%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design,%20synthesis,%20in%20silico%20studies,%20and%20evaluation%20of%20novel%20chalcones%20and%20their%20pyrazoline%20derivatives%20for%20antibacterial%20and%20antitubercular%20activities&rft.jtitle=Medicinal%20chemistry%20research&rft.au=Pola,%20Shivani&rft.date=2020-10-01&rft.volume=29&rft.issue=10&rft.spage=1819&rft.epage=1835&rft.pages=1819-1835&rft.issn=1054-2523&rft.eissn=1554-8120&rft_id=info:doi/10.1007/s00044-020-02602-8&rft_dat=%3Cproquest_cross%3E2438213617%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2438213617&rft_id=info:pmid/&rfr_iscdi=true |